Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E French

Showing results (551-560 of 778) with videos related to

Pageof 78
Sort By:
Leukemia & Lymphoma|January 15, 2019
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndromeFlorian Anzengruber, Desislava Ignatova, Tanja Schlaepfer, et al.
Dermatology (Basel, Switzerland)|December 14, 2017
Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right ThingRalph-Peter Braun, Karina Ulrich, Robert Hunger, et al.
Experimental Dermatology|September 19, 2023
Characterisation of IL-1 family members in Sweet syndrome highlights the overexpression of IL-1β and IL-1R3 as possible therapeutic targetsLaura Calabrese, Francesca Ney, Rui Aoki, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Data in Brief|November 25, 2022
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Journal of Cutaneous Pathology|October 13, 2017
TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonistsCornelia Deubelbeiss, Antonios G A Kolios, Florian Anzengruber, et al.
Seminars in Immunopathology|November 11, 2015
Adverse cutaneous drug eruptions: current understandingW Hoetzenecker, M Nägeli, E T Mehra, et al.
Science (New York, N.Y.)|October 17, 1998
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulinI Viard, P Wehrli, R Bullani, et al.
Photodermatology, Photoimmunology & Photomedicine|October 17, 2019
Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidantsMarkus V Heppt, Benjamin M Clanner-Engelshofen, Enklajd Marsela, et al.
Cancers|September 28, 2023
Innovation in Actinic Keratosis Assessment: Artificial Intelligence-Based Approach to LC-OCT PRO Score EvaluationFabia Daxenberger, Maximilian Deußing, Quirine Eijkenboom, et al.
Pageof 78

Showing results (551-560 of 778) with videos related to

Sort By:
Pageof 78
Leukemia & Lymphoma|January 15, 2019
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndromeFlorian Anzengruber, Desislava Ignatova, Tanja Schlaepfer, et al.
Dermatology (Basel, Switzerland)|December 14, 2017
Evaluation of the National Swiss Skin Cancer Screening Campaign 2013: Do We Do the Right ThingRalph-Peter Braun, Karina Ulrich, Robert Hunger, et al.
Experimental Dermatology|September 19, 2023
Characterisation of IL-1 family members in Sweet syndrome highlights the overexpression of IL-1β and IL-1R3 as possible therapeutic targetsLaura Calabrese, Francesca Ney, Rui Aoki, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Data in Brief|November 25, 2022
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Journal of Cutaneous Pathology|October 13, 2017
TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonistsCornelia Deubelbeiss, Antonios G A Kolios, Florian Anzengruber, et al.
Seminars in Immunopathology|November 11, 2015
Adverse cutaneous drug eruptions: current understandingW Hoetzenecker, M Nägeli, E T Mehra, et al.
Science (New York, N.Y.)|October 17, 1998
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulinI Viard, P Wehrli, R Bullani, et al.
Photodermatology, Photoimmunology & Photomedicine|October 17, 2019
Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidantsMarkus V Heppt, Benjamin M Clanner-Engelshofen, Enklajd Marsela, et al.
Cancers|September 28, 2023
Innovation in Actinic Keratosis Assessment: Artificial Intelligence-Based Approach to LC-OCT PRO Score EvaluationFabia Daxenberger, Maximilian Deußing, Quirine Eijkenboom, et al.
Pageof 78